Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

@inproceedings{Kira2014FingolimodT,
  title={Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension},
  author={Jun-ichi Kira and Y. Itoyama and Seiji Kikuchi and Q G Hao and Takayoshi Kurosawa and Kazuo Nagato and Isao Tsumiyama and Philipp von Rosenstiel and Lixin Zhang-Auberson and Takahiko Saida},
  booktitle={BMC neurology},
  year={2014}
}
BACKGROUND A 6-month phase 2 study of fingolimod demonstrated efficacy and safety in Japanese patients with relapsing-remitting multiple sclerosis (MS). Here we report a 6-month observational extension that evaluated efficacy and safety in patients who received fingolimod continuously for 12 months or who switched from placebo to fingolimod. METHODS Of 147 patients who completed the 6-month core study, 143 entered the extension. Those originally randomized to placebo were re-randomized to… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 2 times. VIEW TWEETS

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Neurological safety of fingolimod: An updated review

Clinical & experimental neuroimmunology • 2017
View 3 Excerpts
Highly Influenced

Neurodegeneration in multiple sclerosis and neuromyelitis optica.

Journal of neurology, neurosurgery, and psychiatry • 2017

References

Publications referenced by this paper.
Showing 1-10 of 20 references

and Drug Administration (FDA): FDA approves first oral drug to reduce MS relapses Sep 22

US Foo
2010. http://www.fda.gov/NewsEvents/ Newsroom/PressAnnouncements/ucm226755.htm. Kira et al. BMC Neurology • 2014
View 2 Excerpts
Highly Influenced

Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

The New England journal of medicine • 2010
View 7 Excerpts
Highly Influenced

Oral fingolimod (FTY720) for relapsing multiple sclerosis.

The New England journal of medicine • 2006
View 5 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…